Research Article

The Presence of Ascites Affects the Predictive Value of HVPG on Early Rebleeding in Patients with Cirrhosis

Table 1

Clinical characteristics of the studied patients.

VariablesPatients ()Ascites group ()Nonascites group ()

Age (y), median (IQR)51.5 (15.75)53.0 (16.00)50.0 (13.50)0.071
Gender, (%)0.607
 Male46 (31.1)53 (67.1)20 (29.0)
 Female102 (68.9)26 (32.9)49 (71.0)
AST (IU/L), median (IQR)33.5 (20.5)34.0 (19.0)33.0 (24.0)0.745
ALT (IU/L), median (IQR)25.0 (15.8)25.0 (19.0)25.0 (14.0)0.917
PLT (109/L), median (IQR)71.5 (72.5)66.0 (71.0)83.0 (78.0)0.118
TBIL (μmol/L), median (IQR)19.9 (10.7)20.5 (12.1)18.9 (9.85)0.138
ALB (g/L), median (IQR)33.4 (7.4)31.2 (7.7)34.7 (7.4)<0.001
INR, median (IQR)1.21 (0.25)1.24 (0.25)1.20 (0.16)0.019
Accepting NSBB, (%)106 (71.6)48 (60.76)58 (84.06)0.002
Ascites, (%)79 (53.4)NANANA
Early rebleeding, (%)15 (10.1)10 (12.66)5 (7.25)0.414
HVPG (mmHg), mean (SD)15.0 (4.66)15.46 (4.52)14.44 (4.79)0.158
Child-Pugh class, (%)<0.001
 Child A62 (41.9)14 (17.72)48 (69.57)
 Child B73 (49.4)53 (67.09)20 (28.99)
 Child C13 (8.8)12 (15.19)1 (1.45)
Etiology, (%)0.165
 Viral87 (58.7)53 (67.09)34 (49.28)
 Alcoholic16 (10.8)8 (10.13)8 (11.59)
 Autoimmunogenic10 (6.7)5 (6.33)5 (7.25)
 Cholestatic5 (3.4)1 (1.27)4 (5.80)
 Other30 (20.3)12 (15.19)18 (26.09)

AST: aspartate aminotransferase; ALT: alanine aminotransferase; PLT: platelets; TBIL: total bilirubin; INR: international normalized; ALB: albumin; NSBB: nonselective beta-blocker; MELD: Model of End-stage Liver Disease; HVPG: hepatic venous pressure gradient; y: years; IQR: interquartile range.